Pembrolizumab Survival Data: Minority Of Patients Are Sur...

Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond 4-5 Years, Checkpoint Inhibitors Are Giving Treatment Options That We Never Had
3 years 104 Du kan ikke administrere denne video
Kategori:
Beskrivelse:
Hossein Borghaei DO, MS @HosseinBorghaei Of Fox Chase Cancer Center discusses Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond 4-5 Years, Checkpoint Inhibitors Are Giving Treatment Options That We Never Had.